Literature DB >> 16411031

The relationship between patient knowledge of hemoglobin levels and health-related quality of life.

J Kallich1, A McDermott, X Xu, P Fayers, D Cella.   

Abstract

BACKGROUND: An anti-anemia drug may improve self-reported quality of life (QOL) partly because patients know their hemoglobin level is rising. In the absence of any published studies on this topic, the authors investigated the association between knowledge of hemoglobin levels and self-reported QOL.
METHODS: The study analyzed health-related QOL (HRQOL) data from five randomized clinical trials of erythropoietic therapy in patients with cancer-related anemia. Patients were asked whether they knew their hemoglobin level and, if so, to report its value. Patients (n=1007) were grouped into three categories depending on the extent and accuracy of hemoglobin level knowledge. HRQOL scale scores were compared between categories.
RESULTS: Only 23.2% of patients reported knowing their hemoglobin level at the end of the study; however, the value was accurate (within 1 g/dl) in 88.0% of these patients. On five of the 11 HRQOL scales studied, there was a significant association between knowledge of hemoglobin level and HRQOL score. However, the magnitude of the mean difference between those who knew vs. those who did not know their hemoglobin was generally below scale thresholds for minimally important differences.
CONCLUSIONS: Patient knowledge of hemoglobin level has a modest association with some aspects of self-reported HRQOL. The magnitude of this association, where it exists, would be unlikely to explain large group differences in HRQOL reports over time, even for patients who know their hemoglobin level.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16411031     DOI: 10.1007/s11136-005-8324-0

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  16 in total

1.  Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system.

Authors:  S B Yellen; D F Cella; K Webster; C Blendowski; E Kaplan
Journal:  J Pain Symptom Manage       Date:  1997-02       Impact factor: 3.612

2.  Fatigue in cancer patients compared with fatigue in the general United States population.

Authors:  David Cella; Jin-Shei Lai; Chih-Hung Chang; Amy Peterman; Mitchell Slavin
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

3.  A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.

Authors:  John A Glaspy; Jaswant Sinh Jadeja; Glen Justice; Alex Fleishman; Gregory Rossi; Alan B Colowick
Journal:  Cancer       Date:  2003-03-01       Impact factor: 6.860

4.  Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.

Authors:  Michael Hedenus; Magnus Adriansson; Jesus San Miguel; Mark H H Kramer; Martin R Schipperus; Eeva Juvonen; Kerry Taylor; Andrew Belch; Albert Altés; Giovanni Martinelli; David Watson; James Matcham; Gregory Rossi; Timothy J Littlewood
Journal:  Br J Haematol       Date:  2003-08       Impact factor: 6.998

5.  Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales.

Authors:  David Cella; David T Eton; Jin-Shei Lai; Amy H Peterman; Douglas E Merkel
Journal:  J Pain Symptom Manage       Date:  2002-12       Impact factor: 3.612

6.  Health-related quality of life of subjects with known and unknown hypertension: results from the population-based Hortega study.

Authors:  Francisco J Mena-Martin; Juan C Martin-Escudero; Fernando Simal-Blanco; Jose L Carretero-Ares; Delfin Arzua-Mouronte; Vicente Herreros-Fernandez
Journal:  J Hypertens       Date:  2003-07       Impact factor: 4.844

7.  Epoetin alfa in patients not on chemotherapy - Canadian data.

Authors:  Ian Quirt; Christine Robeson; Cathy Y Lau; Michael Kovacs; Susan Burdette-Radoux; Sean Dolan; Shou-Ching Tang; Michael McKenzie; Felix Couture
Journal:  Semin Oncol       Date:  2002-06       Impact factor: 4.929

8.  Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa.

Authors:  D L Patrick; D D Gagnon; M J Zagari; R Mathijs; J Sweetenham
Journal:  Eur J Cancer       Date:  2003-02       Impact factor: 9.162

9.  Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.

Authors:  Johan Vansteenkiste; Robert Pirker; Bartomeu Massuti; Fernando Barata; Albert Font; Michael Fiegl; Salvatore Siena; Jenni Gateley; Dianne Tomita; Alan B Colowick; Jaromir Musil
Journal:  J Natl Cancer Inst       Date:  2002-08-21       Impact factor: 13.506

10.  Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy.

Authors:  J A Glaspy; J S Jadeja; G Justice; J Kessler; D Richards; L Schwartzberg; N S Tchekmedyian; S Armstrong; J O'Byrne; G Rossi; A B Colowick
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640

View more
  5 in total

1.  Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial.

Authors:  Eldrin F Lewis; Marc A Pfeffer; Amy Feng; Hajime Uno; John J V McMurray; Robert Toto; Shravanthi R Gandra; Scott D Solomon; Moustafa Moustafa; Iain C Macdougall; Francesco Locatelli; Patrick S Parfrey
Journal:  Clin J Am Soc Nephrol       Date:  2011-01-06       Impact factor: 8.237

Review 2.  Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.

Authors:  Marcello Tonelli; Brenda Hemmelgarn; Tony Reiman; Braden Manns; M Neil Reaume; Anita Lloyd; Natasha Wiebe; Scott Klarenbach
Journal:  CMAJ       Date:  2009-04-30       Impact factor: 8.262

3.  Transfusion of red cells in hematopoietic stem cell transplantation (TRIST): study protocol for a randomized controlled trial.

Authors:  Jason Tay; Alan Tinmouth; Dean Fergusson; David Allan
Journal:  Trials       Date:  2011-09-21       Impact factor: 2.279

4.  Understanding Patient Perspectives of the Impact of Anemia in Chronic Kidney Disease: A United States Patient Survey.

Authors:  Susan Grandy; Eirini Palaka; Nicolas Guzman; Alicia Dunn; Eric T Wittbrodt; Fredric O Finkelstein
Journal:  J Patient Exp       Date:  2022-04-07

5.  Postoperative intravenously administered iron sucrose versus postoperative orally administered iron to treat post-bariatric abdominoplasty anaemia (ISAPA): the study protocol for a randomised controlled trial.

Authors:  Juan Carlos Montano-Pedroso; Elvio Bueno Garcia; Neil Ferreira Novo; Daniela Francescato Veiga; Lydia Masako Ferreira
Journal:  Trials       Date:  2016-04-12       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.